MEREO BIOPHARMA GROUP PLC Proceeds From Borrowings Classified As Financing Activities
MEREO BIOPHARMA GROUP PLC (MREO) reported Proceeds From Borrowings Classified As Financing Activities of GBP 44.38 million for the 12-month period ending 2020-12-31, per its 20-F filed 2021-03-31.
Discontinued › Cash Flow › Financing Activities
ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities · last filed 2021-11-02
| Period end | Proceeds From Borrowings Classified As Financing Activities 6 month | Proceeds From Borrowings Classified As Financing Activities 12 month |
|---|---|---|
| 2020-12-31 | 44.38M GBP 20-F · filed 2021-03-31 | |
| 2020-06-30 | 44.38M GBP 6-K · filed 2021-11-02 | |
| 2018-12-31 | 455.00K GBP 20-F · filed 2020-06-15 | |
| 2017-12-31 | 20.00M GBP 20-F · filed 2020-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |